Regeneron Pharmaceuticals’ (REGN) “Neutral” Rating Reiterated at Cantor Fitzgerald
Cantor Fitzgerald reissued their neutral rating on shares of Regeneron Pharmaceuticals (NASDAQ:REGN – Free Report) in a report published on Wednesday morning, Benzinga reports. The brokerage currently has a $1,015.00 price objective on the biopharmaceutical company’s stock. Several other equities research analysts also recently weighed in on the company. Leerink Partners reissued a “market perform” […]
26 Oct 06:44 · The Cerbat Gem